Cardiovascular

Latest News


Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

Lipoprotein(a) and Cardiovascular Risk

Advancements in Population Health Strategies for Cardiovascular Risk Management

Experts discuss how lipoproteins drive atherosclerotic heart disease, review the different guidelines and recommendations on Lp(a) testing, and insights from clinical trials.

Advancements in Population Health Strategies for Cardiovascular Risk Management

Latest Videos


CME Content


More News

CVD-REAL, the giant study of real-world evidence comparing sodium glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs to treat type 2 diabetes, found a 49% lower risk of all-cause death and a host of other benefits across 6 new, more diverse countries, the study’s lead author told a packed room Sunday at the 67th Scientific Session of the American College of Cardiology in Orlando, Florida.

Adults with obesity have an earlier onset of incident CVD, a greater proportion of life lived with CVD morbidity, and shorter overall survival compared with adults with normal BMI; and the proportion of adults with incident CVD events was significantly higher in adults who were classified as overweight or obese compared with adults with normal BMI, according to a study in JAMA Cardiology.

The annual meeting of the American College of Cardiology (ACC), which runs March 10-12, 2018, in Orlando, Florida, will open with cardiovascular outcomes results for the PCSK9 inhibitor alirocumab (Praluent). The meeting also features updates on anti-inflammatory drugs, the use of SGLT2 inhibitors in heart failure, and how cardiology is shifting to new healthcare delivery models.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo